The effects of erythropoietin on depressive symptoms and neurocognitive deficits inpatients with treatment resistant depression and in patients with remitted bipolar disorder – a proof of concept study

Psykiatrisk Center Rigshospitalet0 个研究点目标入组 84 人开始时间: 2009年4月16日最近更新: 2021年8月2日

适应症

试验速览

暂无简介。

•Sub-study 1:
•Treatment resistant depression, age 18-65 years, Hamilton Depression Scale 17 items (HAMD-17) (Hamilton 1960) score > 17. Treatment resistance is defined by lack of response to at least two different types of antidepressants. Patients are required to not make any changes in their antidepressant medication for at least 2 weeks prior to or during the study.
•Sub-study 2:
•Patients with remitted bipolar disorder, age 18-65 years, HAMD-17 score < 14 and a Young Mania Scale (YMS) score < 14, who have subjective complaints about cognitive problems in a moderate to severe degree in at least 2 of 7 cognitive categories on the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (Fava et al 2006) (score > 4 in these domains).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Exclusion criteria are any significant medical conditions (incl. diabetes, epilepsy, hypertension and thrombosis), pregnancy, smoking, current medication (incl. the contraceptive pill), or first-degree family history of blood clotting, heart disease, seizure disorders or pregnancy.

发起方

Psykiatrisk Center Rigshospitalet